tbuckley/cabot-search huggingface dataset:
Urinalysis in the Evaluation of Proliferative Glomerulonephritis
Authors: Ziv Harel, David L. Simel, Ron Wald
Journal: JAMA (2017)

A 62-year-old woman with hypertension and who had a urinary tract infection with hematuria 1 year ago presented with elevated serum creatinine. Her urinalysis was positive for hematuria, red blood cell casts, and proteinuria. How do you interpret the test results?
Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination
Authors: H Kelly, K Grant
Journal: Eurosurveillance (2009)

Between May and September each year, influenza sentinel surveillance is conducted in general practices in Melbourne and the state of Victoria in southern Australia. We describe the first 11 weeks of sentinel surveillance in 2009 (weeks 18-28), during which time pandemic influenza (H1N1) 2009 virus became established, and investigate the protective effect of seasonal influenza vaccine against laboratory-confirmed infection caused by the pandemic virus. At the time of reporting, the peak ILI activity in 2009 had been reached and was similar to the peak recorded in 2007 but below the peak of 2003. The proportion of cases positive for any influenza virus increased from 6% in the first week of surveillance (week 18) to 59% by week 28, during which time the proportion of influenza viruses detected as pandemic influenza increased from zero to 95%, with at least 91% of all influenza viruses confirmed as pandemic influenza by the eighth week of surveillance (week 25). The median age of all 223 patients with pandemic influenza for whom age was known was 21 years (range 2-63 years) compared with the median age of 53 patients with seasonal H1N1 influenza in 2007 or 2008 of 23 years (range 1-75 years). There was no evidence of significant protection from seasonal vaccine against pandemic influenza virus infection in any age group.
Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.
Authors: Jeeyun Lee, Seung Tae Kim, Kimberly Banks, Richard B. Lanman, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Hyuk Lee, Kyoung-Mee Kim, Won Ki Kang
Journal: Journal of Clinical Oncology (2017)

e15610 Background: It is important to identify biomarkers that predict which patients may benefit from the dual EGFR/HER2 inhibitor, lapatinib in HER2 amplified GC. Methods: We evaluated the efficacy of combining lapatinib with capecitabine and oxaliplatin (CapeOx) treatment in patients with previously untreated, HER2-overexpressing gastric cancer GC with limited metastases. A parallel biomarker study was conducted by IHC, and cfDNA NGS. Results: Thirty-two HER2-overexpressing AGC patients were enrolled between May 2013 – Nov 2015. Complete response (CR) was confirmed in 7 patients. Of 32 patients, we were able to obtain 10 primary-metastasis paired samples. Of 10 paired samples, 6 patients had concordant HER2 results and 4 patients had discordant HER2 positivity between primary and metastasis. Of discordant patients, patient #22 had gastric HER2 2+ but synchronous SCN LN HER2 0 and had progressive disease after one cycle. All of the patients with H index &gt; 200 had tumor reductions. Beyond HER2 overexpression, other genomic alterations (e.g., CRKL amplification) associated with differences in lapatinib sensitivity and/or PFS. One patient with de novo resistance to lapatinib had HER2 and CRKL co-amplifications. We confirmed CRKL overexpression in both tumor tissues and established matched patient-derived cell (PDC) lines via IHC. CRKL knockdown reversed HER2-overexpressed PDC sensitivity to lapatinib. Lastly, serial cfDNA genomics from 11 enrolled patients change during lapatinib treatment demonstrates emergence of MET amplification and myc amplification at progression. Conclusions: This is the first report to show 1) CRKL amplification as a culprit molecule for lapatinib resistance; 2) cfDNA genomics demonstrating tumor evolution during lapatinib treatment which can potentially guide to subsequent treatment. Clinical trial information: 02015169.
GW28-e0598 The effect of DQP on myocardial glucose metabolism in acute myocardial infarction through PI3K-AKT-GSK3β pathway
Authors: Qian Zhang, Xuefeng Zhang, Mingyan Shao, Linghui Lu, Yi Zhang, Qiyan Wang, Chun Li, Wei Wang, Yong Wang
Journal: Journal of the American College of Cardiology (2017)
Amyloid Beta Peptides Block New Synapse Assembly by Nogo Receptor-Mediated Inhibition of T-Type Calcium Channels
Authors: Yanjun Zhao, Sivaprakash Sivaji, Michael C. Chiang, Haadi Ali, Monica Zukowski, Sareen Ali, Bryan Kennedy, Alex Sklyar, Alice Cheng, Zihan Guo, Alexander K. Reed, Ravindra Kodali, Jennifer Borowski, Georgia Frost, Patrick Beukema, Zachary P. Wills
Journal: Neuron (2017)
Abstract 12079: Initial Report From an Emergency-Department-Based Registry of NSTEMI Patients Given Upstream Advanced Oral Antiplatelet Therapy
Authors: Charles V Pollack, Durgesh D Bhandary, Alex Frost, W. Frank Peacock, Deborah B Diercks, Steven H Silber, Sunil V Rao, Sripal Bangalore, Barry Reicher, Lea M Burke, Renato DeRita, Naeem D Khan
Journal: Circulation (2016)

Introduction: There are scant data on use of P2Y12 antagonist therapy upstream of diagnostic angiography (DA), especially when administered in the emergency department (ED) for NSTEMI. We are conducting a multicenter registry to describe patterns of upstream P2Y12 antagonist use and outcomes. Methods: UPSTREAM (NCT02271022) is an ongoing US multicenter, prospective, non-interventional registry of consecutive NSTEMI patients, evaluated in an ED, who are given a loading dose (LD) of ticagrelor, clopidogrel, or prasugrel ≥4h prior to DA, with DA performed ≤72h after ED arrival. All patients are followed to hospital discharge. Patients receiving ticagrelor throughout the index hospitalization and at discharge are also followed for vital status, rehospitalization, bleeding complications, and P2Y12 compliance at 30 days post-discharge. Results: We report in-hospital outcomes of the first 578 patients to have data entry completed at 24 US hospitals. Upstream P2Y12 LD was clopidogrel in 60%, ticagrelor in 39%, and prasugrel in 1%. Of these, 234 (40%) received at least one dose of ticagrelor; 116 (20.1%) were ticagrelor-consistent and had follow-up completed. One-fifth of patients were transferred to an UPSTREAM hospital. Mean age was of the poverall sample was 63 years with 19% older than 75. Approximately 23% of patients had a documented prior MI, 31% had at least one prior stent, and 16% had prior CABG. Chest pain was not part of presenting symptoms in 15%. The median (+/-IQR) time from first ED arrival to LD was 6.7h (+/- 6.8 h); time from LD to DA was 12h (+/- 9.6 h). DA was performed via femoral access in 66% of patients and radially in 34%. Post-DA management was 55% stent, 9% CABG, and 35% medical management. In-hospital CV events (0.7%), including mortality, were infrequent. Only 14 patients (6 [1.0%] CABG-related and 8 non-CABG patients [1.4%]) required RBC transfusion, while 8 (6 CABG-related) required a platelet transfusion. One stent thrombosis event was recorded. Conclusions: Upstream P2Y12 therapy in NSTEMI patients undergoing an invasive strategy is associated with good clinical outcomes and minimal risk of bleeding complications. The most commonly used upstream P2Y12 LD was clopidogrel, but in-hospital switching was common. Updated data will be shown.
Le Programme Européen de Formation à l'Epidémiologie d'Intervention
Authors: A Moren, Mike Rowland, F van Loock, J Giesecke
Journal: Eurosurveillance (1996)

Le Programme Europeen de Formation a l'Epidemiologie d'Intervention (EPIET) fournit une experience pratique en epidemiologie des maladies infectieuses. EPIET a pour but de creer un reseau europeen de professionnels formes a l'utilisation d'une approche standardisee en epidemiologie d'intervention, comprenant le travail sur le terrain, la surveillance, la recherche appliquee, la communication et l'utilisation des informations epidemiologiques pour guider les actions de sante publique. Ce programme est finance par la DGV de la Commission Europeenne.
COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma
Authors: A. Hauschild, M. Santinami, G.V. Long, V. Atkinson, M. Mandala, V. Chiarion Sileni, M.S. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, R. Ji, P. Zhang, B. Mookerjee, J. Legos, R. Kefford, R. Dummer, J. Kirkwood
Journal: Annals of Oncology (2017)
A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies
Authors: J. Tomomatsu, S. Iwasa, H. Saka, S. Takahashi, K. Nakano, S. Morita, M. Inoue, H. Nakahama, Y. Kogure, T. Kakizume, K. Natsume, T. Aoki, C. Quadt, Y. Yamada, Y. Ando
Journal: Annals of Oncology (2017)
GW28-e1126 Cellular repressor of E1A-stimulated genes is a critical determinant of hypertensive vascular remodeling in response to angiotensin II
Authors: Yang Li, Haixu Song, Yanxia Liu, Meili Liu, Chengfei Peng, Mingyu Sun, Yaling Han, Chenghui Yan, Xiaoxiang Tian, Xiaolin Zhang, Yan Zhang, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
Authors: Caroline Kreuzinger, Angelika Geroldinger, Dominiek Smeets, Elena Ioana Braicu, Jalid Sehouli, Julia Koller, Andrea Wolf, Silvia Darb-Esfahani, Korinna Joehrens, Ignace Vergote, Adriaan Vanderstichele, Bram Boeckx, Diether Lambrechts, Hani Gabra, G. Bea A. Wisman, Fabian Trillsch, Georg Heinze, Reinhard Horvat, Stephan Polterauer, Els Berns, Charles Theillet, Dan Cacsire Castillo-Tong
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Most high-grade serous ovarian cancer (HGSOC) patients develop recurrent disease after first-line treatment, frequently with fatal outcome. This work aims at studying the molecular biology of both primary and recurrent HGSOC. Experimental Design: Gene expression profiles of matched primary and recurrent fresh-frozen tumor tissues from 66 HGSOC patients were obtained by RNA sequencing. Clustering analyses and pairwise comparison of the profiles between matched samples and subsequent functional alignment were used for the identification of molecular characteristics of HGSOC. Results: Both primary and recurrent HGSOC samples presented predominant gene expression differences in their microenvironment, determined by a panel of genes covering all major pathways of immune activation together with a number of genes involved in the remodeling of extracellular matrix and adipose tissues. Stratifying tumor tissues into immune active and silent groups, we further discovered that although some recurrent tumors shared the same immune status as their primary counterparts, others switched the immune status, either from silent to active or active to silent. Interestingly, genes belonging to the B7-CD28 immune checkpoint family, known for their major role as negative regulators of the immune response, were overexpressed in the immune active tumors. Searching for potential tumor antigens, CEACAM21, a member of the carcinoembryonic antigen family, was found to be significantly overexpressed in immune active tissues in comparison with the silent ones. Conclusions: The results illustrate the complexity of the tumor microenvironment in HGSOC and reveal the molecular relationship between primary and recurrent tumors, which have multiple therapeutic implications. Clin Cancer Res; 23(24); 7621–32. ©2017 AACR.
Community-wide outbreak of hepatitis A in Latvia in 2008 – an update
Authors: J Perevoščikovs, I Lucenko, S Magone, A Brila, J Curikova, H Vennema
Journal: Eurosurveillance (2009)

An outbreak of hepatitis A has been ongoing in Latvia with 2,817 confirmed cases reported between 20 November 2007 and 31 December 2008. Initially the spread of infection was due to transmission among drug users and other high-risk groups, as well as several outbreaks in Riga (affecting a school and a restaurant), but in the second half of the year led to a community-wide increase in the number of cases. Molecular analysis of 100 strains showed that 95 belonged to genotype IA, of which 89 were identical and six were single nucleotide variants of the same sequence.
Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy
Authors: A.H. Ingles Garces, J.E. Ang, M. Ameratunga, M. Chenard-Poirier, D. Dolling, R. Sundar, S. Kaye, J. de Bono, U. Banerji, J. Lopez
Journal: Annals of Oncology (2017)
Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis
Authors: Yingmei Wang, Limei Hu, Ping Ji, Fei Teng, Wenyan Tian, Yuexin Liu, David Cogdell, Jinsong Liu, Anil K. Sood, Russell Broaddus, Fengxia Xue, Wei Zhang
Journal: Journal of Hematology & Oncology (2017)
Effusive-Constrictive Pericarditis After Pericardiocentesis
Authors: Kye Hun Kim, William R. Miranda, Larry J. Sinak, Faisal F. Syed, Rowlens M. Melduni, Raul E. Espinosa, Garvan C. Kane, Jae K. Oh
Journal: JACC. Cardiovascular imaging (2017)
Piani di lotta contro la pandemia di influenza in Europa
Authors: J F Aguilera, W J Paget
Journal: Eurosurveillance (2001)

L'Organizzazione Mondiale della Sanita raccomanda fermamente a tutti i paesi di predisporre per tempo piani multidisciplinari per prevenire e controllare la prossima pandemia di influenza. Abbiamo condotto un'indagine tra i membri dello European Influenza Surveillance Schemes, EISS, sui metodi di sorveglianza dell'influenza, che comprendeva un set di domande sulla pianificazione della lotta contro la pandemia. Tutti tranne un paese hanno attivato un piano o sono in procinto di farlo. Un coordinamento di questi diversi piani nazionali a livello europeo contribuirebbe probabilmente a migliorarne l'impatto e l'efficacia.
Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms
Authors: A.C. Picornell, I. Echavarria Diaz-Guardamino, E.L. Alvarez Castillo, S. Lopez-Tarruella Cobo, Y. Jerez, K. Hoadley, J. Parker, M. del Monte-Millán, R. Ramos Medina, J. Gayarre, I. Ocaña, M. Cebollero, T. Massarrah, F. Moreno Antón, J.A. García-Saenz, H. Gomez Moreno, A.I. Ballesteros Garcia, M. Ruiz Borrego, C. Perou, M. Martin Jimenez
Journal: Annals of Oncology (2017)
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Authors: Irene M. Min, Enda Shevlin, Yogindra Vedvyas, Marjan Zaman, Brian Wyrwas, Theresa Scognamiglio, Maureen D. Moore, Weibin Wang, Susan Park, Spencer Park, Suraj Panjwani, Katherine D. Gray, Andrew B. Tassler, Rasa Zarnegar, Thomas J. Fahey, Moonsoo M. Jin
Journal: Clinical Cancer Research (2017)

Purpose: Poorly differentiated thyroid cancer and anaplastic thyroid cancer (ATC) are rare yet lethal malignancies with limited treatment options. Many malignant tumors, including papillary thyroid cancer (PTC) and ATC, are associated with increased expression of ICAM-1, providing a rationale for utilizing ICAM-1-targeting agents for the treatment of aggressive cancer. We developed a third-generation chimeric antigen receptor (CAR) targeting ICAM-1 to leverage adoptive T-cell therapy as a new treatment modality.Experimental Design: ICAM-1 CAR T cells were applied to multiple malignant and nonmalignant target cells to investigate specific target cell death and "off-tumor" toxicity in vitroIn vivo therapeutic efficacy of ICAM-1 CAR T cells was examined in ATC mouse models established from a cell line and patient-derived tumors that rapidly develop systemic metastases.Results: ICAM-1 CAR T cells demonstrated robust and specific killing of PTC and ATC cell lines in vitro Interestingly, although certain ATC cell lines showed heterogeneous levels of ICAM-1 expression, addition of cytotoxic CAR T cells induced increased ICAM-1 expression such that all cell lines became targetable. In mice with systemic ATC, a single administration of ICAM-1 CAR T cells mediated profound tumor killing that resulted in long-term remission and significantly improved survival. Patient-derived ATC cells overexpressed ICAM-1 and were largely eliminated by autologous ICAM-1 CAR T cells in vitro and in animal models.Conclusions: Our findings are the first demonstration of CAR T therapy against both a metastatic, thyroid cancer cell line and advanced ATC patient-derived tumors that exhibit dramatic therapeutic efficacy and survival benefit in animal studies. Clin Cancer Res; 23(24); 7569-83. ©2017 AACR.
Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence
Authors: P.D. d'Arienzo, E. Amir, A.R. Lewis, L. Magdalani, W. Mansoor, R.A. Hubner, J.W. Valle, M.G. McNamara
Journal: Annals of Oncology (2017)
A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers
Authors: A. Zimmer, C. Peer, L. Cao, E. Kohn, S. Lipkowitz, C. Annunziata, J. Trepel, M-J. Lee, L. Mikkilineni, M. Gatti-Mays, A. Nunes, S. Soltani, W.D. Figg, N. Houston, E. Nichols, J-M. Lee
Journal: Annals of Oncology (2017)
Prognosis of desmoid tumours initially managed with surveillance only at all anatomical locations
Authors: W.J. van Houdt, A.K. Patel, R.L. Jones, M.J. Smith, A. Miah, C. Benson, S. Zaidi, C. Messiou, E. Moskovic, D.C. Strauss, A.J. Hayes, O. Husson, W.T.A. van der Graaf
Journal: Annals of Oncology (2017)
Abstract 11979: Relationship between the QT Interval and Outcome in Low-Flow Low-Gradient Aortic Stenosis With Low LVEF
Authors: Abdellaziz Dahou, Oumhani Toubal, Marie-Annick Clavel, Jonathan Beaudoin, Julien Magne, Patrick Mathieu, François Philippon, Jean G Dumesnil, Rishi Puri, Henrique B Ribeiro, Éric Larose, Josep Rodés-Cabau, Philippe Pibarot
Journal: Circulation (2016)

Background: The QT interval has been shown to be associated with cardiovascular events. There is no data available on the association between the QT interval and left ventricular (LV) function and on its impact on prognosis in patients with low LV ejection fraction (LVEF), low-flow, low-gradient (LF-LG) aortic stenosis (AS). The objectives of this study were to examine the relationship between the corrected QT interval (QTc) and LV function and outcome in patients with LF-LG AS and low LVEF. Methods: Ninety-three patients (73±10 years; 74% men) with LF-LG AS (i.e. mean gradient [MG] &lt;40 mmHg and indexed aortic valve area [AVAi] ≤0.6 cm2/m2) and reduced LVEF (≤40%) were prospectively included in this analysis and 63 (68%) of them underwent aortic valve replacement (AVR) within 3 months following inclusion. QTc was calculated with the Bazett formula. Prolonged QTc was defined as QTc&gt; 450 ms in men and &gt;470 ms in women. The severity of AS was assessed by the projected AVA (AVAproj) at normal flow rate. LV global longitudinal strain (GLS) was measured by 2D speckle tracking and expressed in absolute value
Field epidemiology training in Europe faces a bright future
Authors: Arthur  L. Reingold
Journal: Eurosurveillance (2001)

It is fitting that the group of articles describing various field epidemiology training programmes published here should appear in 2001, the 50th anniversary of the Epidemic Intelligence Service (EIS) of the Centers for Disease Control and Prevention (CDC). Were he still alive today, Alex Langmuir (founder of EIS) would be delighted to see how well established and successful such training programmes have become in Europe. Similar ‘on-the-job’ training programmes intended to provide health professionals with the practical skills needed to conduct relevant and timely applied epidemiological investigations in the ‘real world’ of public health are also burgeoning in Latin America, Asia, and Africa. Some of these training programmes are being developed and offered jointly with local academic institutions, others involve formal partnerships with CDC itself, and some are stand alone efforts of local public health agencies.
Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial
Authors: J. Remon, A. Martinez-Marti, E. Carcereny Costa, J. Zeron-Medina Cuairan, I. Sansano, J.L. Mate, N. Pardo, S. Cedres, A. Navarro, A.M. Martinez de castro, T. Moran, E. Felip Font
Journal: Annals of Oncology (2017)
Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26
Authors: S. Karim, K. Ding, P. Bradbury, P. Ellis, N. Mittman, X. Xiaoqun Sun, M. Millward, G. Liu, S. Sun, M.R. Stockler, V. Cohen, N. Blais, R. Sangha, M. Boyer, R. Sasidharan, C. Lee, F.A. Shepherd, G. Goss, L. Seymour, N.B. Leighl
Journal: Annals of Oncology (2017)
Abstract 14002: Randomized Comparison of Once-daily Fixed Combination versus Free-drug Combination of Three Antihypertensive Agents
Authors: Giuseppe Marazzi, Francesco Pelliccia, Giuseppe Campolongo, Luca Cacciotti, Sara Poggi, Alessandra Tanzilli, Martina Di Iorio, Giuseppe Rosano
Journal: Circulation (2016)

Background: A 3 drug combination strategy is often needed to achieve blood pressure (BP) targets. However, the optimal strategy of drug administration remains unknown. The aim of this study was to compare the efficacy and safety of once-daily fixed (ODF) combination versus free-drug combination of 3 antihypertensive agents. Methods: The ONE&amp;ONLY Trial was a randomized, prospective, multicenter trial. A total of 731 hypertensive patients (pts) treated with the combination of perindopril plus indapamide or amlodipine were screened initially. The 305 pts who did not meet the BP targets after 4 weeks were randomized to ODF combination of perindopril 10 mg + indapamide 2.5 mg + amlodipine 5 or 10 mg (N=154, fixed group) versus free-drug combination of the 3 antihypertensive agents (N=151, free group). Primary end-points were the differences in clinic BP between the 2 groups after 12 weeks. Secondary end-points included intragroup differences in clinic BP during the study period and achievement of BP targets at week 12. Safety and compliance were also assessed during the trial. Results: Baseline characteristics were similar among the treatment groups. At 12-weeks, the fixed group had lower systolic BP (SBP) (125±12 vs 129±11 mm Hg, p=0.002) and similar diastolic BP (DBP) (82±9 vs 84±7 mm Hg, p=0.082) compared to the free group. With respect to baseline measures, changes in BP with fixed combination were statistically significant for systolic (-18.9± 11.2 mm Hg, p&lt;0.01), and diastolic values (-6.3±5.7 mm Hg, p&lt;0.01). On free combination, changes vs. baseline in SBP and DBP, conversely, were of borderline significance. BP targets at week 12 were more commonly reached with fixed than free combination (89% [137 of 154] and 80% [121 of 151], respectively, p=0.048). Safety was not significantly different between the 2 groups. Conversely, compliance was significantly greater in the fixed-group vs the free-group (94% [144 of 154] and 85% [129 of 151], respectively, p=0.034). Conclusion: This randomized trial shows in a large population of hypertensive pts that ODF combination of perindopril, indapamide, and amlodipine is as effective and safe as free combination of the 3 drugs, although is associated with a significantly greater compliance. ClinicalTrials.gov ID: NCT02710539
Real life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubünden) and Liechtenstein
Authors: B.L. Hartmann, W. Oberaigner, H. Frick, L. Weiss, T. Winder, K. Philipp-Abbrederis, C. Herrmann, M.Q. Huynh, G. Spizzo, C.M. Lang, A. Seeber, J. Schneider, E. Wöll, P. Mosler, R. Greil, M. Rössle, H. Rumpold, G. Gastl, R. von Moos, A.H. Lang
Journal: Annals of Oncology (2017)